Pipeline

Currently, we have 6 ongoing programmes that are either in full development or ready to start clinical trials in humans.

As of April 2020, several patent applications describing our innovative formulations, drug delivery methods and target indications have been filed to the European Patent Office for review. Consequently, we cannot publicly disclose these activities until we receive the necessary patent protection for our programmes. However, Cannovex is open for partnerships and is always willing to provide additional information to interested parties (info@cannovex.com

Programme

Indication

Pre-Clinical

Formulation &
Drug Delivery

Phase 1

Phase 2

Phase 3

Market Authorisation

CNX-001

Undisclosed

Expected start of phase 1 in Q1-Q2 2021

CNX-002

Undisclosed

In formulation development

CNX-003

Undisclosed

In formulation development

CNX-004

Undisclosed

In Pre-clinical development

CNX-005

Undisclosed

In Pre-clinical development

CNX-006

Undisclosed

In Pre-clinical development

Our Partners

Cannovex BV
BE0656.491.644

Agoralaan Abis
3590 Diepenbeek
Belgium

cannovex web 2

© 2020 – Cannovex BV – All rights reserved

Tel: +32 11 28 69 00
E-mail: info@cannovex.com